L Morrissey

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein et al. · The Lancet Oncology · 2017 · 430 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Lecia V. Sequist, Rebecca S. Heist, Alice T. Shaw et al. · Annals of Oncology · 2011 · 368 citations · Full text

Medicine, Molecular Genetics, Oncology +13

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Rebecca S. Heist, Mari Mino–Kenudson, Lecia V. Sequist et al. · Journal of Thoracic Oncology · 2012 · 205 citations · Full text

Medicine, Genetics, Oncology +14

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Martin Reck, Fiona Taylor, John R. Penrod et al. · Journal of Thoracic Oncology · 2017 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14